Assyro AI

FDA Orange Book · active-ingredient family

Desvenlafaxine

Desvenlafaxine is approved in 2 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:DESVENLAFAXINE · NDA 204150

2

Brand (NDA)

0

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · tablet, extended release

ProductApplicantApplicationTEApproved
DESVENLAFAXINERLD×2ALEMBIC PHARMS LTDNDA 204150Mar 04, 2013
KHEDEZLA×2OSMOTICA PHARM CORPNDA 204683Jul 10, 2013

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Desvenlafaxine — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.